Hormone receptor expression in breast cancer: Postanalytical issues

Journal of Clinical Pathology

Volumn 66, Issue 6, 2013, Pages 478-484

  Lee, Ming ^a,b   Lee, Cheok Soon ^a,b   Tan, Puay Hoon ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CELL HETEROGENEITY; CELLULAR DISTRIBUTION; HORMONE RESPONSE; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR INTERACTION; PATHOLOGIST; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR GROWTH;

BREAST CANCER; BREAST PATHOLOGY; IMMUNOHISTOCHEMISTRY; QUALITY ASSURANCE; QUALITY CONTROL;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING;

EID: 84878325303     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201148     Document Type: Review

References (85)

1. McGuire WL, Horwitz KB, Pearson OH, et al. Current status of estrogen and progesterone receptors in breast cancer. Cancer 1977;39:2934-47. (Pubitemid 8130407)
2. Osborne CK. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 1985;12:317-26. (Pubitemid 16214558)
3. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 2001;34:347-52. (Pubitemid 32777841)
4. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw 2009;(7 Suppl 6):S1-21; quiz S22-3.
5. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
6. Osborne CK, Yochmowitz MG, Knight WA III, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884-8. (Pubitemid 11205652)
7. Nicholson RI, Bouzubar N, Walker KJ, et al. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer 1991;27:908-13.
8. Bartlett JM, Rea D, Rimm DL. Quantification of hormone receptors to guide adjuvant therapy choice in early breast cancer: better methods required for improved utility. J Clin Oncol 2011;29:3715-16.
9. Payne SJ, Bowen RL, Jones JL, et al. Predictive markers in breast cancer - the present. Histopathology 2008;52:82-90. (Pubitemid 350265187)
10. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44. (Pubitemid 47244357)
11. Chen WY, Colditz GA. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 2007;4:415-23. (Pubitemid 47039692)
12. Carlson RW, Hudis CA, Pritchard KI. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw 2006;4:971-9. (Pubitemid 44845487)
13. Nofech-Mozes S, Vella ET, Dhesy-Thind S, et al. Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer. Clin Oncol (R Coll Radiol) 2012;24:684-96.
14. Uy GB, Laudico AV, Carnate JM Jr, et al. Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients. Clin Breast Cancer 2010;10:154-9.
15. Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol 2009;22:1457-67.
16. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;(21 Suppl 2):S8-15.
17. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol 2010;(23 Suppl 2):S52-9.
18. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68. (Pubitemid 28144151)
19. McGuire WL. Estrogen receptors in human breast cancer. J Clin Invest 1973;52:73-7.
20. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9:1980-9. (Pubitemid 36687616)
21. Jensen EV, Desombre ER, Hurst DJ, et al. Estrogen-receptor interactions in target tissues. Arch Anat Microsc Morphol Exp 1967;56:547-69.
22. Clarke RB. Steroid receptors and proliferation in the human breast. Steroids 2003;68:789-94. (Pubitemid 37532401)
23. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25:3846-52. (Pubitemid 47477259)
24. Jalava P, Kuopio T, Huovinen R, et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res 2005;25:2535-42. (Pubitemid 41044745)
25. Barnes DM, Harris WH, Smith P, et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-51. (Pubitemid 26370738)
26. Mackey JR. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer? J Clin Oncol 2011;29:1504-6.
27. Yamashita H, Yando Y, Nishio M, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 2006;13:74-83.
28. Stendahl M, Ryden L, Nordenskjold B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006;12:4614-18. (Pubitemid 44297812)
29. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 2006;98:1571-81. (Pubitemid 44680908)
30. Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer 2004;11:267-75.
31. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-54. (Pubitemid 39627082)
32. Press MF, Xu SH, Wang JD, et al. Subcellular distribution of estrogen receptor and progesterone receptor with and without specific ligand. Am J Pathol 1989;135:857-64. (Pubitemid 20009495)
33. Thomas J, Hanby A, Pinder S, et al. Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. Breast J 2008;14:33-8.
34. Kim R, Kaneko M, Arihiro K, et al. Extranuclear expression of hormone receptors in primary breast cancer. Ann Oncol 2006;17:1213-20. (Pubitemid 44288211)
35. Rexhepaj E, Brennan DJ, Holloway P, et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 2008;10:R89.
36. Thike AA, Chng MJ, Fook-Chong S, et al. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology 2001;33:21-5. (Pubitemid 32222505)
37. Giri DD, Dundas SA, Nottingham JF, et al. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989;15:575-84. (Pubitemid 20022907)
38. Giri DD, Danger field VJ, Lonsdale R, et al. Immunohistology of oestrogen receptor and D5 antigen in breast cancer: correlation with oestrogen receptor content of adjacent cryostat sections assayed by radioligand binding and enzyme immunoassay. J Clin Pathol 1987;40:734-40.
39. Detre S, SaclaniJotti G, et al. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8.
40. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81. (Pubitemid 29220854)
41. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4.
42. Edge S, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 2010.
43. Daly MB. Tamoxifen in ductal carcinoma in situ. Semin Oncol 2006;33:647-9. (Pubitemid 44828130)
44. Francis GD, Dimech M, Giles L, et al. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol 2007;60:1277-83. (Pubitemid 350084552)
45. Fitzgibbons PL, Murphy DA, Hammond ME, et al. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med 2010;134:930-5.
46. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-30. (Pubitemid 30075056)
47. Rhodes A, Jasani B, Balaton AJ, et al. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000;53:292-301. (Pubitemid 30180402)
48. Rhodes A, Jasani B, Balaton AJ, et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000;53:688-96.
49. Stanford JL, Szklo M, Brinton LA. Estrogen receptors and breast cancer. Epidemiol Rev 1986;8:42-59.
50. Wood B, Junckerstorff R, Sterrett G, et al. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions. Pathology 2007;39:391-5. (Pubitemid 47221462)
51. Usami S, Moriya T, Amari M, et al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol 2007;37:250-5. (Pubitemid 47090677)
52. Hanley KZ, Birdsong GG, Cohen C, et al. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations. Cancer 2009;117:279-88.
53. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 2006;15:167-72. (Pubitemid 44268916)
54. Douglas-Jones AG, Collett N, Morgan JM, et al. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol 2001;54:951-5. (Pubitemid 34032891)
55. Cavaliere A, Sidoni A, Scheibel M, et al. Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett 2005;218:117-21. (Pubitemid 40082708)
56. Gregory DM, Parfrey PS. The breast cancer hormone receptor retesting controversy in Newfoundland and Labrador, Canada: lessons for the health system. Healthc Manage Forum 2010;23:114-18.
57. Idirisinghe PK, Thike AA, Cheok PY, et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 2010;133:416-29.
58. Bogina G, Bortesi L, Marconi M, et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 2011;459:1-10.
59. Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-9. (Pubitemid 26300127)
60. Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol 2010;7:139-47.
61. Tamimi RM, Colditz GA, Hazra A, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 2012;131:159-67.
62. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
63. Leclercq G. Molecular forms of the estrogen receptor in breast cancer. J Steroid Biochem Mol Biol 2002;80:259-72. (Pubitemid 34304150)
64. Falette NS, Fuqua SA, Chamness GC, et al. Estrogen receptor gene methylation in human breast tumors. Cancer Res 1990;50:3974-8. (Pubitemid 20225616)
65. Horwitz KB. How do breast cancers become hormone resistant? J Steroid Biochem Mol Biol 1994;49:295-302. (Pubitemid 24240614)
66. Marotti JD, Collins LC, Hu R, et al. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2010;23:197-204.
67. Speirs V, Shaaban AM. Hormone receptors in defining breast cancer prognosis - time for a rethink? Nat Clin Pract Oncol 2007;4:204-5. (Pubitemid 46510525)
68. Saji S, Omoto Y, Shimizu C, et al. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 2002;62:4849-53. (Pubitemid 34984402)
69. Skliris GP, Leygue E, Watson PH, et al. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 2008;109:1-10.
70. Bartlett JM, Ellis IO, Dowsett M, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 2007;25:4423-30. (Pubitemid 350013848)
71. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
72. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46. (Pubitemid 46640570)
73. Badve S, Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 2009;62:6-12.
74. Karn T, Ruckhaberle E, Hanker L, et al. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat 2011;130:409-20.
75. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010;120:293-308.
76. O' Connor SM, Beriwal S, Dabbs DJ, et al. Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors. Appl Immunohistochem Mol Morphol 2010;18:268-72.
77. Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25:4772-8. (Pubitemid 350086480)
78. Geurts-Moespot J, Leake R, Benraad TJ, et al. Twenty years of experience with the steroid receptor external quality assessment program - the paradigm for tumour biomarker EQA studies. On behalf of the EROTC Receptor and Biomarker Study Group. Int J Oncol 2000;17:13-22.
79. Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 2010;7:725-32.
80. Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med 2010;134:1697-701.
81. Roepman P, Horlings HM, Krijgsman O, et al. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 2009;15:7003-11.
82. Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) 2009;23:133-42.
83. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059-65.
84. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29. (Pubitemid 46224240)
85. Desch CE, McNiff KK, Schneider EC, et al. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol 2008;26:3631-7.